Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 10/20 | 0.42 |
| ▸ | RAB9A | P51151 | 10/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.41 |
| ▸ | RELA | Q04206 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534317 | 0.87 | BAZ2B (0.52) | NPC1RAB9ACYP1A2ACHEALDH1A1 | |
| SCHEMBL22872917 | 0.80 | NPC1 (0.47) | NPC1RAB9AACHE | |
| SCHEMBL30831920 | 0.80 | NPC1 (0.47) | NPC1RAB9AACHE | |
| SCHEMBL14117297 | 0.77 | ALDH1A1 (0.54) | KMT2AMEN1CYP1A2CYP2C19POLB | |
| SCHEMBL5467633 | 0.77 | ALDH1A1 (0.54) | KMT2AMEN1CYP1A2CYP2C19POLB | |
| SCHEMBL610795 | 0.77 | PYGL (0.53) | KMT2ANPC1RAB9AMEN1SMN1; SMN2 | |
| SCHEMBL4142239 | 0.76 | ACHE (0.46) | KMT2ANPC1RAB9AACHEOPRD1 | |
| SCHEMBL13499144 | 0.76 | ACHE (0.46) | KMT2ANPC1RAB9AACHEOPRD1 | |
| Hydrochloric Acid SCHEMBL12505566 | 0.76 | ALDH1A1 (0.53) | KMT2AMEN1CYP1A2CYP2C19POLB | |
| Hydrochloric Acid SCHEMBL353579 | 0.76 | ALDH1A1 (0.53) | KMT2AMEN1CYP1A2CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630759-B1 | COMPOUNDS USEFUL AS ION CHANNEL INHIBITORS FOR THE TREATMENT OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2024-05-01 | — | — | EP | disclosed |
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFQUE (FR) | 2024-03-19 | — | — | US | disclosed |
| US-20210009581-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CHU NANTES (FR) | 2021-01-14 | — | — | US | disclosed |
| EP-3630759-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | Centre National De La Recherche Scientifique (FR) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215557-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932638-B2 | Ion channel inhibitor compounds for cancer treatment | CACNA1E, KCNA1, KCNT1 | KMT2A 2663/4885NPC1 531/4885RAB9A 1013/4885 |
| US-20210009581-A1 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT | CACNA1E, KCNA1, KCNT1 | KMT2A 2663/4885NPC1 531/4885RAB9A 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.